Notoginsenoside R1 alleviates TNF-α-induced pancreatic β-cell Min6 apoptosis and dysfunction through up-regulation of miR-29a

Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2379-2388. doi: 10.1080/21691401.2019.1624368.

Abstract

Diabetes mellitus (DM) is a metabolic disorder that seriously harms human health. Notoginsenoside R1 (NGR1) can be used in various diseases. We explored consequents of NGR1 on tumour necrosis factor (TNF)-α-stimulated Min6 and rat primary islets β cells. The results were that TNF-α significantly cut down cell activity, raised cell apoptosis and iNOS expression and decreased insulin secretion in Min6 and rat primary islets β cells. NGR1 alleviated TNF-α-treated cell dysfunctions. In addition, miR-29a was positively regulated by NGR1 in TNF-α-treated Min6 and rat primary islets β cells. miR-29a knockdown damaged protection roles of NGR1 through cutting down cell activity and insulin secretion, raising apoptosis and iNOS in TNF-α-treated Min6 and rat primary islets β cells. The phosphorylation of Wnt3a, β-catenin and the rate of p/t-AKT/PI3K was all increased, while p/t-GSK3β was decreased by the administration with NGR1. In conclusion, NGR1 alleviated TNF-α-stimulated Min6 and rat primary islets β cells apoptosis and worn roles via positively regulating miR-29a. This process might be through actuation of Wnt/β-catenin and PI3K/AKT/GSK3β signal ways.

Keywords: Diabetes mellitus; PI3K/AKT/GSK3β; Wnt/β-catenin; miR-29a; notoginsenoside R1.

Publication types

  • Retracted Publication

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Ginsenosides / pharmacology*
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Insulin-Secreting Cells / cytology*
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / metabolism
  • Mice
  • MicroRNAs / genetics*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Up-Regulation / drug effects*
  • Wnt Signaling Pathway / drug effects

Substances

  • Ginsenosides
  • MIRN29 microRNA, mouse
  • MicroRNAs
  • Tumor Necrosis Factor-alpha
  • Phosphatidylinositol 3-Kinases
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt
  • notoginsenoside R1